Live Breaking News & Updates on Tengfei Zhang

Stay updated with breaking news from Tengfei zhang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Density matters for better battery material performance

Zinc cheap, abundant, environmentally friendly may be the answer to better batteries, but there’s a major problem: Aqueous zinc ion batteries (AZIBs) cannot match lithium-ion batteries in term . ....

Jun Zhou , Cuiping Han , Meilin Li , Qingming Liu , Tengfei Zhang , Senlin Li , Fanbin Zeng , Shenzhen Institute Of Advanced Technology , Energy Materials , Chinese Academy Of Sciences , Institute Of Technology , Carbon Neutrality , Shenzhen Institute , Advanced Technology , Chinese Academy , Aqueous Zinc Ion Batteries , Zinc Ion Batteries , Covalent Organic Frameworks , Cathode Material ,

Harnessing the Potential of High-Performance Organic Cathodes

Zinc, which is inexpensive, abundant, and ecologically friendly, could be the answer to better batteries, but there is a huge issue: In terms of power output, aqueous zinc ion batteries (AZIBs) cannot compete with lithium-ion batteries. To see what electrode material composition could bring AZIBs up to par, a Chinese research team created two organic frameworks with the same elements but arranged differently. ....

Fanbin Zeng , Tengfei Zhang , Meilin Li , Cuiping Han , Skyla Baily , Qingming Liu , Jun Zhou , Senlin Li , Research Foundation , Vehicle Battery Technology Industry , Vehicle Battery Technology , Chinese Academy Of Sciences , China Postdoctoral Science Foundation , Energy Materials , Tsinghua University , Study Co , Outstanding Youth Basic Research Project Of Shenzhen , Shenzhen Institute Of Advanced Technology , Towngas Energy Academy , National Natural Science Foundation Of China , Study Co First Author , Shenzhen Institute , Advanced Technology , Chinese Academy , Vehicle Battery Technology Industry Focus , Guangdong Basic ,

Density Key to Enhanced Battery Performance, Study Reveals

Density Key to Enhanced Battery Performance, Study Reveals
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Jun Zhou , Cuiping Han , Meilin Li , Tengfei Zhang , Senlin Li , Fanbin Zeng , Qingming Liu , Shenzhen Institute Of Advanced Technology , Towngas Energy Academy , Tsinghua University , Production Services , Outstanding Youth Basic Research Project Of Shenzhen , National Natural Science Foundation Of China , Energy Materials , Chinese Academy Of Sciences , Research Foundation , China Postdoctoral Science Foundation , Institute Of Technology , Editorial Services , Carbon Neutrality , Shenzhen Institute , Advanced Technology , Chinese Academy , Towngas Energy , National Natural Science Foundation , Guangdong Basic ,

Gulf Resources Announces Management Changes

Gulf Resources Announces Management Changes
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Amin Yang , Tengfei Zhang , Xiaobin Liu , Liu Xiaobin , Corporate Governance Committee , Exchange Commission , Shouguang City Haoyuan Chemical Company Limited , Daying County Haoyuan Chemical Company Limited , Shouguang Yuxin Chemical Industry Co , Company On , Compensation Committee , Shouguang Hengde Salt Industry Co , Securities Exchange , Gulf Resources Inc , Annual Meeting , Chief Executive Officer , Corporate Governance , Gulf Resourced , Gulf Resources , Shouguang Hengde Salt Industry , Elemental Bromine , Securities Act , Securities Exchange Act , Cautionary Statement ,

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

Objective To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, and docetaxel compared with placebo, trastuzumab, and docetaxel for untreated HER2 positive metastatic breast cancer.

Design Randomised, double blind, placebo controlled, multicentre, phase 3 trial.

Setting 40 centres in China between 6 May 2019 and 17 January 2022.

Participants 590 female patients (median age 52 (interquartile range 46-58) years) with untreated HER2 positive metastatic breast cancer.

Interventions Eligible patients were randomised 1:1 to receive either oral pyrotinib (400 mg once daily) or placebo, both combined with intravenous trastuzumab (8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2) on day 1 of each 21 day cycle. Randomisation was stratified by treatment history of trastuzumab in the (neo)adjuvant setting and hormone receptor status. Patients, investigators, a ....

Eteläuomen Läi , Pconclusions Pyrotinib , Jiaman Lin Hengrui , Tengfei Zhang , Demets Obrien Fleming , Kaijing Zhao Hengrui , Eastern Cooperative Oncology Group , Human Genetic Resource Administration Of China , Drug Administration , Jiangsu Hengrui Pharmaceuticals , China National Medical Products Administration , Innovation Fund For Medical Sciences , Response Evaluation Criteria , Solid Tumors , National Cancer Institute , Common Terminology Criteria , Adverse Events , Good Clinical Practice , Human Genetic Resource Administration , Jiaman Lin , Kaijing Zhao , Good Publication Practice , Medical Sciences , Jiangsu Hengrui , Open Access , Creative Commons Attribution Non Commercial ,